Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Los acuerdos de resolución de conflictos con Reverse Payments en el sector farmacéutico / / Javier Framiñán Santas
| Los acuerdos de resolución de conflictos con Reverse Payments en el sector farmacéutico / / Javier Framiñán Santas |
| Autore | Framiñán Santas Javier |
| Pubbl/distr/stampa | Madrid : , : Marcial Pons Ediciones Jurídicas y Sociales, , 2014 |
| Descrizione fisica | 1 online resource (276 páginas) |
| Disciplina | 344.460416 |
| Soggetto topico |
Pharmacy - Law and legislation - Spain
Farmacia - Legislación y normativa - España Pharmacy management Administración de farmacias |
| Soggetto genere / forma | Libros electronicos. |
| ISBN | 84-9123-288-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | spa |
| Record Nr. | UNINA-9910671312003321 |
Framiñán Santas Javier
|
||
| Madrid : , : Marcial Pons Ediciones Jurídicas y Sociales, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in Pharma Business Management and Research [[electronic resource] ] : Volume 1 / / edited by Lars Schweizer, Theodor Dingermann, Otto Quintus Russe, Christian Jansen
| Advances in Pharma Business Management and Research [[electronic resource] ] : Volume 1 / / edited by Lars Schweizer, Theodor Dingermann, Otto Quintus Russe, Christian Jansen |
| Autore | Schweizer Lars |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Springer Nature, 2020 |
| Descrizione fisica | 1 online resource (X, 85 p. 11 illus.) |
| Disciplina | 615.19 |
| Soggetto topico |
Pharmaceutical technology
Health care management Health services administration Medical laws and legislation Pharmacy Pharmacy management Pharmaceutical Sciences/Technology Health Care Management Medical Law Pharmacoeconomics and Health Outcomes |
| Soggetto non controllato |
Pharmaceutical Sciences/Technology
Health Care Management Medical Law Pharmacy Pharmacoeconomics and Health Outcomes Pharmaceutics Health Care Pharmacology Pharma Management Market Access Regulatory Affairs Research & Development Quality Control Open Access Industrial chemistry & chemical engineering Health economics Medical & healthcare law Pharmacy / dispensing |
| ISBN | 3-030-35918-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Introduction: Trends and developments in the pharmaceutical and life sciences industry -- Chapter 2. Relevance of instruments for measurements of Quality of Life in the AMNOG Context -- Chapter 3. The quality management system for R&D project and portfolio management in a pharmaceutical company -- Chapter 4. Brexit and Its Impact on Pharmaceutical Law - Implications for global pharma companies -- Chapter 5. Implementation of Measurable and Sustainable Actions to Improve Employee’s Engagement and Business Performance - Global Medical Clinical & Regulatory Affairs (GMCRA) – A Role Model at Fresenius Kabi -- Chapter 6. Leadership Models and Work Behavior: An Empirical Analysis of Consequences of Authentic and Transformational Leadership -- Chapter 7. Alliance Management at Merck - Establishing an operational 100-day plan for alliance launches and management. |
| Record Nr. | UNINA-9910380742003321 |
|
Schweizer Lars
|
||
| Springer Nature, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antimicrobial Resistance [[electronic resource] ] : Global Challenges and Future Interventions / / edited by Sabu Thomas
| Antimicrobial Resistance [[electronic resource] ] : Global Challenges and Future Interventions / / edited by Sabu Thomas |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (XIII, 230 p. 20 illus., 16 illus. in color.) |
| Disciplina | 615 |
| Soggetto topico |
Pharmaceutical technology
Pharmacy management Drug resistance Microbiology Pharmaceutical Sciences/Technology Pharmacoeconomics and Health Outcomes Drug Resistance Applied Microbiology Resistència als medicaments Microbiologia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-3658-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1) The Evolution of Microbial Defense Systems against Antimicrobial Agents -- 2) Carbapenem Resistance in Gram-negative bacilli: Mechanisms and Challenges -- 3) Influence of Antimicrobials on the Gut Microbiota -- 4) Influence of Abiotic Factors in the Emergence of Antibiotic Resistance -- 5) Polluted Coastal and Estuarine Environments – A Potential Reservoir for AMR Determinants in Various Pathogenic Bacteria -- 6) AMR in Animal Health: Issues and One Health Solutions for LMICs -- 7) Antifungal Resistance: Current Concepts -- 8) 'Planetary Health’ Perspectives and Alternative Approaches to Tackle the AMR Challenge -- 9) Use of Bacterial Cell Wall Recycle Inhibitors to Combat AMR in Bacteria -- 10) Status quo of Omics Technologies in Analyzing the Genetic Mediators of Antimicrobial Resistance at Sub-MIC Concentrations. |
| Record Nr. | UNINA-9910416106703321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applying Comparative Effectiveness Data to Medical Decision Making [[electronic resource] ] : A Practical Guide / / edited by Carl Asche
| Applying Comparative Effectiveness Data to Medical Decision Making [[electronic resource] ] : A Practical Guide / / edited by Carl Asche |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Adis, , 2016 |
| Descrizione fisica | 1 online resource (VIII, 113 p. 16 illus., 12 illus. in color.) |
| Disciplina | 610 |
| Soggetto topico |
Pharmacy management
Pharmacoeconomics and Health Outcomes |
| ISBN | 3-319-23329-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Introduction to Comparative Effectiveness Research -- 2. Randomized Controlled Trials -- 3. Observational Studies -- 4. Evaluating Published CER Evidence -- 5. Epidemiological Principles Applied to CER -- 6. The Question of Value -- 7. Medical Decision Making: When Evidence and Medical Culture Clash -- 8. The Value of Prevention. |
| Record Nr. | UNINA-9910254512103321 |
| Cham : , : Springer International Publishing : , : Imprint : Adis, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ASHP's management pearls [[electronic resource] /] / [edited by] Deborah Swartwood Ash
| ASHP's management pearls [[electronic resource] /] / [edited by] Deborah Swartwood Ash |
| Pubbl/distr/stampa | Bethesda, Md., : American Society of Health-System Pharmacists, c2009 |
| Descrizione fisica | 1 online resource (121 p.) |
| Disciplina | 615/.1068 |
| Altri autori (Persone) | AshDeborah Swartwood |
| Soggetto topico | Pharmacy management |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-58528-281-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Mentoring : mentoring for recruitment and retention / Sara J. White -- Employing a 360-degree performance tool : around the pharmacy in 360 degrees / Lisa Michener -- Journal club makeover / Michael A. Fotis -- Solving the call-in conundrum : help! I need somebody! / Elizabeth Schmitz -- Suggestions for easing a new practitioner into management : who me? a manager? / Kristi K. Killelea -- Career renewal : maintaining fulfillment and happiness throughout a career / Sara J. White -- Establishing county-wide concentration and dosing unit standards for high-risk IV medications / John H. Eastham -- Successes and challenges of VTE protocol implementation / Della Abboud -- Clinical communication : is your staff dialed in? / Rachel Hroncich -- Intervention follow-through : is IT being done? / Georgeanne Lemanowicz -- Documenting interventions : a practice of the past / E. Thomas Carey -- Today's formulary management / Tammy Cohen and Stanley S. Kent -- Reimbursement for pharmaceuticals : I know you're bluffing / Anne T. Jarrett -- Revenue optimization : dollars and sense? Are your revenues optimized? / Nancy T. Nguyen and Rita Shane -- Purchasing strategy to maximize health-system cost savings and improve procurement safety / Joel A. Hennenfent, Larry J. Koesterer, and Annette M. Karageanes. |
| Record Nr. | UNINA-9910464558203321 |
| Bethesda, Md., : American Society of Health-System Pharmacists, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Budget-Impact Analysis of Health Care Interventions [[electronic resource] ] : A Practical Guide / / by Josephine Mauskopf, Stephanie R. Earnshaw, Anita Brogan, Sorrel Wolowacz, Thor-Henrik Brodtkorb
| Budget-Impact Analysis of Health Care Interventions [[electronic resource] ] : A Practical Guide / / by Josephine Mauskopf, Stephanie R. Earnshaw, Anita Brogan, Sorrel Wolowacz, Thor-Henrik Brodtkorb |
| Autore | Mauskopf Josephine |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Adis, , 2017 |
| Descrizione fisica | 1 online resource (224 pages) |
| Disciplina | 610.285 |
| Soggetto topico |
Pharmacy management
Medical research Health informatics Pharmacoeconomics and Health Outcomes Quality of Life Research Health Informatics |
| ISBN | 3-319-50482-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Introduction to Budget-Impact Analysis -- 2. Determining the Analytic Framework -- 3. Estimating the Diagnosed, Treated, and Eligible Population -- 4. Estimating the Treatment Mix -- 5. Estimating Treatment-Related Costs -- 6. Estimating Condition-Related Costs -- 7. The Computing Framework and Calculations -- 8. Uncertainty Analysis -- 9. Validation -- 10. Software and Computer Interface -- 11. Reporting Budget-Impact Analyses -- 12. Additional Pragmatic Topics -- 13. Alternative Interventions -- 14. Creating Your Own Budget-Impact Analyses Today and Tomorrow. |
| Record Nr. | UNINA-9910254485803321 |
|
Mauskopf Josephine
|
||
| Cham : , : Springer International Publishing : , : Imprint : Adis, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical Epidemiology of Chronic Liver Diseases [[electronic resource] /] / edited by Robert J. Wong, Robert G. Gish
| Clinical Epidemiology of Chronic Liver Diseases [[electronic resource] /] / edited by Robert J. Wong, Robert G. Gish |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (349 pages) |
| Disciplina | 614.4273 |
| Soggetto topico |
Hepatology
Gastroenterology Epidemiology Pharmacy management Gastroenterology Pharmacoeconomics and Health Outcomes |
| ISBN | 3-319-94355-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Principles of Clinical Epidemiology.– Understanding Study Design for Clinical Epidemiology Studies -- Understanding the Interpretation of Disease Incidence and Prevalence -- Understanding Survival Analyses -- Epidemiology of Liver Disease – Worldwide Perspective -- Epidemiology of Liver Disease in the U.S -- Alcoholic Liver Disease -- Hepatitis B Virus – The Asian Perspective -- Hepatitis B Virus – The African Perspective -- Hepatitis B Virus – Western Perspective -- Hepatitis D Virus -- Hepatitis C Virus -- Hepatitis A and Hepatitis E Virus -- Nonalcoholic Fatty Liver Disease -- Hepatocellular Carcinoma -- Autoimmune Liver Diseases and Cholestatic Liver Diseases -- Genetic and Inherited Liver Diseases -- Cryptogenic Liver Diseases and other -- Summary. |
| Record Nr. | UNINA-9910337491903321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Controlled Substance Management in Chronic Pain [[electronic resource] ] : A Balanced Approach / / edited by Peter S. Staats, Sanford M. Silverman
| Controlled Substance Management in Chronic Pain [[electronic resource] ] : A Balanced Approach / / edited by Peter S. Staats, Sanford M. Silverman |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 |
| Descrizione fisica | 1 online resource (XII, 323 p. 32 illus., 18 illus. in color.) |
| Disciplina | 616.0472 |
| Soggetto topico |
Pain medicine
Pharmacotherapy Pharmacy management Primary care (Medicine) Pain Medicine Pharmacoeconomics and Health Outcomes Primary Care Medicine |
| ISBN | 3-319-30964-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1 Scope of the pain problem -- 2 Scope of the problem: Intersection of chronic pain and addiction -- 3 Evidence-based treatment for chronic pain with opioids -- 4 Opioid pharmacology -- 5 Pharmacokinetics -- 6 Benzodiazepines, Alcohol and Stimulant Use in Combination with Opioid Use -- 7 Marijuana and cannabinoids for pain -- 8 Adjuvant agents in chronic pain therapy -- 9 Complications of opioid therapy -- 10 Risk mitigation strategies -- 11 Naloxone Treatment of Opioid Overdose -- 12 From Patient Evaluation to Opioid Overdose Prevention: Ten Steps to Make the Law Work for You and Your Patients -- 13 Treating the difficult patient -- 14 Controlled Substance Management: Exit Strategies for the Pain Practitioner -- 15 Alternatives to opiates in the management of non-cancer related pain -- Appendix A: American Society of Interventional Pain Physicians (ASIPP) Guidelines for Responsible Opioid Prescribing in Chronic Non-Cancer Pain -- Appendix B: Sample Opioid Agreement/Informed Consent -- Appendix C: Opioid Risk Tool -- Appendix D: Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP®-R) -- Appendix E: McGill Pain Questionnaire. |
| Record Nr. | UNINA-9910254556003321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cost Effectiveness Modelling for Health Technology Assessment [[electronic resource] ] : A Practical Course / / by Richard Edlin, Christopher McCabe, Claire Hulme, Peter Hall, Judy Wright
| Cost Effectiveness Modelling for Health Technology Assessment [[electronic resource] ] : A Practical Course / / by Richard Edlin, Christopher McCabe, Claire Hulme, Peter Hall, Judy Wright |
| Autore | Edlin Richard |
| Edizione | [1st ed. 2015.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Adis, , 2015 |
| Descrizione fisica | 1 online resource (XIII, 208 p. 86 illus., 3 illus. in color.) |
| Disciplina | 362.1068 |
| Soggetto topico |
Pharmacy management
Medical research Health informatics Health economics Pharmacoeconomics and Health Outcomes Quality of Life Research Health Informatics Health Economics |
| ISBN | 3-319-15744-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Acknowledgements -- Contents -- Chapter 1: Economic Evaluation, Cost Effectiveness Analysis and Health Care Resource Allocation -- 1.1 Introduction -- 1.2 Scarcity, Choice and Opportunity Cost -- 1.3 Types of Economic Evaluation -- 1.3.1 Cost Benefit Analysis (CBA) -- 1.3.2 Cost Effectiveness Analysis (CEA) -- 1.3.3 Cost Utility Analysis (CUA) -- 1.4 Incremental Cost Effectiveness Ratios (ICERs) -- 1.4.1 Simple and Extended Dominance -- 1.4.2 The Net Benefit Approach -- 1.5 Summary -- References -- Chapter 2: Finding the Evidence for Decision Analytic Cost effectiveness Models -- 2.1 Introduction -- 2.2 Choosing Resources to Search for Evidence -- 2.3 Designing Search Strategies -- 2.4 Searching for Existing Cost effectiveness Models -- 2.4.1 Where to Look -- 2.4.2 Search Strategy, Concepts, Terms and Combinations -- 2.4.3 Search Filters, Database Limits and Clinical Queries -- 2.5 Searching for Clinical Evidence -- 2.5.1 Finding the Evidence on Incidence, Prevalence and Natural History of a Disease -- 2.5.2 Finding the Evidence on the Clinical Effectiveness of Health Interventions -- 2.5.3 Database Limits and Clinical Queries -- 2.6 Finding the Evidence on Health-Related Quality of Life and Health State Preferences -- 2.6.1 Where to Look -- 2.6.2 Search Strategy, Concepts, Terms and Combinations -- 2.6.3 Search Filters, Database Limits and Clinical Queries -- 2.7 Finding Evidence on Resource Use and Costs -- 2.7.1 Where to Look -- 2.7.2 Search Strategy, Concepts, Terms and Combinations -- 2.7.3 Search Filters, Database Limits and Clinical Queries -- 2.8 Tracking and Reporting Search Activities -- 2.9 Quality Assessment Tools -- 2.10 Summary -- References -- Chapter 3: Building a Decision Tree Cost Effectiveness Model -- 3.1 Introduction -- 3.2 What Is a Decision Model? -- 3.3 Key Elements of a Decision Tree.
3.4 Costs, Benefits and Complexity -- 3.5 Exercise Building a Decision Tree -- 3.6 Summary -- References -- Chapter 4: Uncertainty, Probabilistic Analysis and Outputs from Cost Effectiveness Analyses -- 4.1 Introduction -- 4.2 Sources of Uncertainty in Cost Effectiveness Models -- 4.2.1 Sampling Variation -- 4.2.2 Extrapolation -- 4.2.3 Generalisability -- 4.2.4 Model Structure -- 4.2.5 Methodological Uncertainty -- 4.3 Analytic Responses to Uncertainty in CEA -- 4.3.1 One-Way Sensitivity Analysis -- 4.3.2 Multiway Sensitivity Analysis -- 4.3.3 Threshold Analysis -- 4.3.4 Analysis of Extremes -- 4.4 Probabilistic Sensitivity Analysis (PSA) -- 4.5 Outputs from Probabilistic Analysis -- 4.6 Some Problems with ICERs -- 4.7 Summary -- References -- Chapter 5: Introduction to Markov Cost Effectiveness Models -- 5.1 Introduction -- 5.2 Why Use Markov Models? -- 5.3 Health States -- 5.4 Transition Probabilities -- 5.5 Markov Trace -- 5.6 Cycle Length, Time Horizon and Discounting -- 5.7 Summary -- References -- Chapter 6: Probability Distributions for Effectiveness Parameters -- 6.1 Introduction -- 6.2 What Do We Mean by Effectiveness Parameters? -- 6.2.1 Obtaining Information on Effectiveness -- 6.3 Choosing Distributions for Effectiveness Parameters -- 6.3.1 Fitting a Distribution -- 6.4 Beta Distribution for Probabilities -- 6.5 Dirichlet Distribution for Multinomial Probabilities -- 6.6 Normal Distribution for Log-Relative Risk -- 6.7 Survival Analysis for Time-to-Event Data -- 6.7.1 The Exponential Distribution -- 6.7.2 The Weibull Distribution -- 6.7.3 The Gompertz Distribution -- 6.7.4 Choice of Distribution for Time-to-Event Data -- 6.8 Parameter Correlation in Survival Analysis -- 6.9 Summary -- References -- Chapter 7: Probability Distributions for Cost and Utility Parameters -- 7.1 Introduction -- 7.2 Distributions for Cost Parameters. 7.2.1 The LogNormal Distribution -- 7.2.1.1 LogNormal via Method of Moments I -- 7.2.1.2 LogNormal via Method of Moments II -- 7.2.2 The Gamma Distribution -- 7.3 Distributions for Utility Parameters -- 7.3.1 Distributional Characteristics of the Utility Scale -- 7.4 Characterising Uncertainty for Expected Utility Values Close to 1.0 -- 7.4.1 Characterising Uncertainty for Expected Utility Values Away from 1.0 -- 7.4.2 Logical Ordering for Utilities in Cost Effectiveness Models -- 7.4.3 Health State-Specific Side Effect Utility Decrements -- 7.5 Summary -- References -- Chapter 8: Correlated Parameters and the Cholesky Decomposition -- 8.1 Introduction -- 8.2 Correlated Parameters -- 8.3 Defining a Set of Correlated Parameters -- 8.4 The Cholesky Decomposition -- 8.5 What If I Need a Cholesky Decomposition for a Different Number of Variables? -- 8.6 Interpreting the Cholesky Decomposition -- 8.7 Summary -- Appendix -- Appendix 8.1: Extending the Cholesky Decomposition for More Than Three Correlated Parameters -- Chapter 9: Building a Markov Cost Effectiveness Model in Excel -- 9.1 Introduction -- 9.2 The Model -- 9.3 Modelling in Excel -- 9.4 Constructing the Parameter Table -- 9.5 Programming Your Model -- 9.6 Adding a Discount Rate, Costs and Utilities -- 9.7 Adding the Calculation of the Deterministic Incremental Cost Effectiveness Ratio (ICER) -- 9.8 Summary -- Chapter 10: Making a Markov Model Probabilistic -- 10.1 Introduction -- 10.2 Deterministic and Probabilistic Cost Effectiveness Analysis -- 10.3 Making Model Parameters Stochastic -- 10.4 Obtaining a Probabilistic Sensitivity Analysis from a Stochastic Model -- 10.5 Exercise: Probabilistic Effectiveness Parameters -- 10.6 Exercise: Probabilistic Cost and Utility Parameters -- 10.7 Exercise: Incorporating the Cholesky Decomposition -- 10.8 Summary -- Appendix. Appendix 10.1: Optimising Visual Basic Macros in Excel -- Chapter 11: Outputs from Probabilistic Sensitivity Analysis -- 11.1 Introduction -- 11.2 Scatter Plots on the Cost Effectiveness Plane -- 11.3 Cost Effectiveness Acceptability Curves (CEACs) -- 11.4 Cost Effectiveness Acceptability Frontiers (CEAFs) -- 11.5 Scatter Plots, CEACs and CEAF Exercises -- 11.6 Summary -- References -- Chapter 12: Investing in Health Care, Research and the Value of Information -- 12.1 Introduction -- 12.2 Uncertainty and Health-Care Reimbursement Decision-Making Processes -- 12.3 Investing in Innovative Health Technologies -- 12.4 Net Benefit Probability Map and Managing Decision Uncertainty -- 12.5 Delaying a Reimbursement Decision for More Research -- 12.5.1 Uncertainty in Decision Making and the Cost of Making the Wrong Decision -- 12.5.2 Expected Value of Perfect Information and the Value of Sample Information -- 12.5.3 Calculating the Expected Value of Perfect Information -- 12.6 Disaggregating the Value of Information: Expected Value of Perfect Parameter Information and the Expected Value of Sample Information -- 12.6.1 Expected Value of Perfect Parameter Information -- 12.6.2 Expected Value of Sample Information -- 12.7 Exercise: Constructing the Net Benefit Probability Map and Calculating the Value of Perfect Information -- 12.7.1 Calculating the Expected Value of Perfect Information -- 12.8 Summary -- References -- Chapter 13: Value of Information in Health Technology Regulation and Reimbursement -- 13.1 Introduction -- 13.2 Value of Information Analysis for Research Prioritisation -- 13.3 Value of Information Analysis for Research Design -- 13.3.1 Calculating the Expected Net Present Value of Sample Information -- 13.4 Is Decision Theory Ready to Inform Trial Design? -- 13.4.1 Structuring a Decision Problem. 13.4.2 Evidence Synthesis and Model Parameterisation -- 13.4.3 Computational and Statistical Challenges -- 13.4.4 Adoption by Regulatory Organisations and Reimbursement Agencies -- 13.4.5 Adoption by Public Research Commissioners and Clinical Trialists -- 13.4.6 Industrial Development of Health Technologies -- 13.5 Value of Information in the Evolving Regulatory and Reimbursement Environments -- 13.6 Summary -- Appendix -- Appendix 13.1: General Monte Carlo Sampling Algorithm for Calculation of Population ENPVSI -- References. |
| Record Nr. | UNINA-9910300166503321 |
|
Edlin Richard
|
||
| Cham : , : Springer International Publishing : , : Imprint : Adis, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Decision Making in a World of Comparative Effectiveness Research [[electronic resource] ] : A Practical Guide / / edited by Howard G. Birnbaum, Paul E. Greenberg
| Decision Making in a World of Comparative Effectiveness Research [[electronic resource] ] : A Practical Guide / / edited by Howard G. Birnbaum, Paul E. Greenberg |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Adis, , 2017 |
| Descrizione fisica | 1 online resource (XVI, 289 p. 18 illus., 7 illus. in color.) |
| Disciplina | 615.1 |
| Soggetto topico |
Pharmacy management
Health economics Statistics Pharmaceutical technology Pharmacoeconomics and Health Outcomes Health Economics Statistics for Life Sciences, Medicine, Health Sciences Pharmaceutical Sciences/Technology |
| ISBN | 981-10-3262-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | I. Introduction -- 1. Introducing Decision Making in a World of Comparative Effectiveness Research -- 2. Perspectives on Decision Making in a World of Comparative Effectiveness: Views from Diverse Constituencies -- II. The Future of CER for Evidence Developers: Perspectives from Pharmaceutical Decision Makers -- 3. Perspectives on the Use of CER by Life Sciences Executives: An Interview with Mike Bonney -- 4. Perspectives on the Use of CER by Life Sciences Executives: An Interview with a Senior Executive at an International Life Science Company -- 5. CER: A Pharmaceutical Industry Perspective on Outlook, Dilemmas, and Controversies -- 6. Impact of Comparative Effectiveness Research on Drug Development Strategy and Innovation -- 7. Pricing of Pharmaceuticals: Current Trends and Outlook, and the Role of CER -- III. Evolving Stakeholder Considerations: Patients, Physicians, Regulators and Payers -- 8. Are Real-World Data and Evidence Good Enough to Inform Healthcare and Health Policy Decision Making? -- 9. Translating CER Evidence to Real-World Decision-Making: Some Practical Considerations -- 10. Decision Making by Public Payers -- 11. Patient and Stakeholder Engagement in Designing Pragmatic Clinical Trials -- 12. Policy Considerations: Ex-U.S. Payers and Regulators -- 13. Perspectives on the Common Drug Review (CDR) Process at the Canadian Agency for Drugs and Technologies in Health (CADTH) -- 14. Evaluating Non-Pharmaceutical Technologies at the Canadian Agency for Drugs and Technologies in Health (CADTH) -- 15. Challenges and Opportunities in the Dissemination of CER Information to Physicians and Payers: A Legal Perspective -- 16. Legal Considerations in a World of CER -- IV. Emerging Challenges, Methods and Applications of CER: Real-world and Big Data -- 17. Application of CER to Promote Adherence to Clinical Practice Guidelines -- 18. Challenges in Developing and Assessing CER for Medical Technology -- 19. Evidence Generation Using Big Data: Challenges and Opportunities -- 20. Indirect Comparisons Using Clinical Trial Data: 5 Years Later -- 21. Decision-Making with Machine Learning in Our Modern, Data-Rich Healthcare Industry. |
| Record Nr. | UNINA-9910254651303321 |
| Singapore : , : Springer Singapore : , : Imprint : Adis, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
